Brain

The World Wellness Show, LLC Gains Support of Dr. Clint Steele & NeuroINFINITI - a Revolutionary Cognitive Brain and Nervous System Diagnostic Technology

Retrieved on: 
Wednesday, April 10, 2024
Education, Interview, NIH, Sport, Chiropractic, Health, Communication, Partnership, Host, Disease, Patient, Brain, Medicine, Knowledge, Nursing

The World Wellness Show, an organization dedicated to providing doctors educational, holistic health and wellness interviews, is now accepting NEW DOCTOR INTERVIEWS.

Key Points: 
  • The World Wellness Show, an organization dedicated to providing doctors educational, holistic health and wellness interviews, is now accepting NEW DOCTOR INTERVIEWS.
  • Doctors wanting to share their holistic message around the world go to www.TheWorldWellnessShow.com to schedule an online interview.
  • Join the World Wellness Show in their mission of providing global education on proactive health and wellness practices.
  • To learn more about The World Wellness Show and get involved or become a sponsor, visit www.TheWorldWellnessShow.com.

C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market

Retrieved on: 
Friday, April 26, 2024
Research, Managed Care, Pharmaceutical, Consumer, Mental Health, Health Technology, Clinical Trials, Science, Biotechnology, Neurology, Seniors, Health, Epidemiology, Biogen, Brain, Protein, Learning, Donanemab, Clarity, Prognosis, Partnership, PET, Pathology, Non-fungible token, Dementia, Alzheimer's disease, Hoshiko Yamane, DSM-IV codes, Peptide, Diagnosis, Biomarker, Ageing, Clinical trial, Medical imaging

Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.

Key Points: 
  • Hoshiko, who’s based in Kyoto, Japan, has a well-established background as a neuroscientist focused on the commercialization aspects of the field.
  • Other research has found that Japan has the highest proportion of people with dementia of any country.
  • We believe our partnership with Mediford Corporation will unlock many opportunities and possibilities.
  • Mediford Corporation is known for providing clinical and non-clinical analysis that supports each stage of drug research and development, including advanced treatment options.

Swave Photonics Developing World’s First True Holographic Display Technology To Power Reality-First Spatial Computing

Retrieved on: 
Thursday, April 25, 2024
Wearables, Mobile Technology, Technology, Semiconductor, Photography, Nanotechnology, Audio, Video, Hardware, Artificial Intelligence, Consumer Electronics, QBIC, Stanford University, Society for Information Display, Luminate, Brain, Holography, AI, CMOS, Texas Instruments, Nausea, XR, Software, Meta, 3D, Silicon, Headache, Fatigue, Smartglasses, PCM, Multimedia, Smoke

Swave Photonics, the true holographic display company, today announced its development of the world’s first 3D holographic display technology for compact extended reality (XR) form factors like smart glasses.

Key Points: 
  • Swave Photonics, the true holographic display company, today announced its development of the world’s first 3D holographic display technology for compact extended reality (XR) form factors like smart glasses.
  • The chip-based technology will enable AI-powered spatial computing with a reality-first user experience, where digital elements complement, learn from, and interact with the physical world.
  • View the full release here: https://www.businesswire.com/news/home/20240425346947/en/
    Swave Photonics, the true holographic display company, today announced its development of the world’s first 3D holographic display technology for compact extended reality (XR) form factors like smart glasses.
  • (Photo: Business Wire)
    The first application for the HXR display technology will be low-cost, light weight, AR smart glasses with all-day battery life.

BrightFocus Foundation Announces $10M in New Funding Across Brain and Vision Research, Celebrates Historic Diversity of Grant Award Recipients

Retrieved on: 
Thursday, April 25, 2024
Optical, Managed Care, Mental Health, General Health, Philanthropy, Women, Neurology, Fund Raising, Foundation, Science, Biotechnology, Consumer, Nursing, Health, Research, Brain, Genetics, Inflammation, Health equity, Dementia, Woman, Doctor of Philosophy, Artificial intelligence, BrightFocus Foundation, Macular degeneration, Multimedia, Diagnosis, Immune system, Clinical trial, Immunity, Neuron, Glaucoma, Quality of life, WHAM, Pharmaceutical industry

Pictured is BrightFocus Macular Degeneration Research grant recipient Yara Lechanteur, MD, PhD.

Key Points: 
  • Pictured is BrightFocus Macular Degeneration Research grant recipient Yara Lechanteur, MD, PhD.
  • 57% of new grant recipients identify as a member of a non-white racial or ethnic group.
  • BrightFocus currently has 157 active neuroscience research projects, a $43 million investment, and 119 active vision research projects, a $30 million investment.
  • BrightFocus Foundation’s research programs are supported entirely by private donor contributions from the public and corporate and foundation grants; BrightFocus receives no government funding.

Equinox Hotels Revolutionizes Sleep Tourism with Inaugural Global Sleep Symposium

Retrieved on: 
Wednesday, April 24, 2024
Other Health, Other Travel, Other Consumer, Lodging, Destinations, General Health, Travel, Women, Men, Science, Vacation, Consumer, Other Science, Health, Research, Relaxation, Foodservice, Lead, Brain, University, Psychology, TED (conference), Yoga, Sleep, Hotel, Fasting, Movement, University of California, Berkeley, Melksham, Multimedia, Central nervous system, Equinox, Regeneration, Electronic, Longevity, Sound, UC

Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.

Key Points: 
  • Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.
  • This visionary two-day overnight event is set to redefine the landscape of sleep tourism by uniting global experts in sleep health and performance with Equinox Hotel's dynamic programming centered on movement, nutrition, regeneration, and community.
  • The two-day symposium signifies the culmination of years of boundary-pushing sleep innovation, positioning Equinox Hotels as the preeminent nexus for leaders in the sleep industry and enthusiasts alike, to converge, collaborate, and propel the discourse on sleep science and sleep tourism to new heights.
  • The Equinox Hotels Global Sleep Symposium transcends mere discussion; it offers an immersive experience aimed at enhancing every aspect of sleep quality, providing attendees with firsthand interactions to elevate their sleep understanding and practice.

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Retrieved on: 
Wednesday, April 24, 2024
Health, Pharmaceutical, Technology, Artificial Intelligence, Oncology, Brain, Fox Chase Cancer Center, AIDS, Lung cancer, AI, Pancreatic cancer, Ambulatory care, Hematology, Machine learning, MD, Doctor of Philosophy, National Cancer Institute, Research, Ohio State University, Artificial intelligence, Disease, Science, Patient, NCI, Physician, Neoplasm, Central nervous system, Diagnosis, Drug development, Associate, Sanofi, Kishor, Medical director, AstraZeneca, Pharmaceutical industry

The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.

Key Points: 
  • The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.
  • Each webinar will feature a presentation from a Lantern collaborator, advisor, or researchers followed by a live Q&A.
  • These sessions provide a deep dive into the company’s research, collaborations, clinical trials and expected goals for the drug or AI development initiatives.
  • Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial.

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Retrieved on: 
Wednesday, April 24, 2024
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, METIS, Efficacy, Safety, Patient, Deep learning, International, TIGER, Abstract, Survival, Metastasis, Lung cancer, MD, Baptist Health South Florida, Glioblastoma, ASCO, Radiation therapy, Pembrolizumab, Treatment, Brain, Society, Platinum, CDT, Clinical trial, Annual general meeting, Baptist Health, NSCLC, Medical imaging

METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.

Key Points: 
  • METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC.
  • “We are honored to present the results of the METIS clinical trial as a late-breaking abstract this year at ASCO, the largest global oncology conference,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • “Patients with brain metastases from non-small cell lung cancer need more treatment options.
  • The METIS trial demonstrated that TTFields Therapy delayed intracranial progression while preserving neurological function, which is critical for these underserved patients.

Sheppard Mullin Lands Healthcare Partner Stephanie Marcantonio in New York

Retrieved on: 
Wednesday, April 24, 2024
Professional Services, Health, Legal, Practice Management, Managed Care, General Health, Credit Suisse, Sale, Pharmacy, Morgan Stanley, Brain, Health care, Humana, Deutsche Bank, DXC Technology, Growth, J. P. Morgan, Veritas Capital, Acquisition, KKR, Villanova University, Rehabilitation, Marcantonio Raimondi

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Healthcare partner Stephanie Marcantonio has joined the firm’s New York office.

Key Points: 
  • Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Healthcare partner Stephanie Marcantonio has joined the firm’s New York office.
  • Marcantonio joins from Crowell & Moring LLP where she was a partner and a member of its corporate steering committee.
  • In Marcantonio’s healthcare practice, she represents post-acute healthcare providers and other healthcare entities in connection with divestitures, mergers, affiliations and joint ventures, many of which also include significant real estate components.
  • “Investing in our transactional capabilities, particularly within the healthcare sector, remains a key priority for the firm,” said Luca Salvi, chair of Sheppard Mullin.

International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums announce partnership to advance IV training for sonographers

Retrieved on: 
Tuesday, April 23, 2024
Surgery, Medical Devices, Medical Supplies, Hospitals, Training, Radiology, Health, Education, Oncology, Brain, Radiation, Society, Kidney, CME, Safety, Contrast-enhanced ultrasound, Android, Risk, GE HealthCare, Scope of practice, Partnership, IPhone, Nebraska Medicine, CEUS, Nursing, Thomas Jefferson University, Patient, Agent handling, Google Images, MRI, Accreditation, Multimedia, Assistant, ICUS, Definity, Medical imaging

The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) today announced an educational partnership to help train sonographers to perform contrast-enhanced ultrasound (CEUS) examinations and administer intravenous ultrasound contrast agents.

Key Points: 
  • The International Contrast Ultrasound Society (ICUS) and Northwest Imaging Forums (NWIF) today announced an educational partnership to help train sonographers to perform contrast-enhanced ultrasound (CEUS) examinations and administer intravenous ultrasound contrast agents.
  • View the full release here: https://www.businesswire.com/news/home/20240423887525/en/
    The new IV training program follows the recent update of the sonographer Scope of Practice, which expands the role of sonographers in administering ultrasound contrast agents.
  • The new Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer was released last month by the Society of Diagnostic Medical Sonographers.
  • During a CEUS exam, an ultrasound contrast agent is injected intravenously to improve the clarity and functionality of the ultrasound image.

Dyno Therapeutics to Present on Breakthroughs in AI Methods for AAV Capsid Design at ASGCT Annual Congress and SynBioBeta Global Synthetic Biology Conference

Retrieved on: 
Tuesday, April 23, 2024
Health, Technology, Genetics, Artificial Intelligence, Pharmaceutical, Biotechnology, Brain, Abstract, Machine learning, Cell, Conference, Research, AAV, Intelligence, Engineering, Patient, Eye, Gene, Society

That same week Dyno Therapeutics will also be giving two talks on the theme of Machine Learning at SynBioBeta’s Global Synthetic Biology Conference held from May 6-9th, 2024 in San Jose, California.

Key Points: 
  • That same week Dyno Therapeutics will also be giving two talks on the theme of Machine Learning at SynBioBeta’s Global Synthetic Biology Conference held from May 6-9th, 2024 in San Jose, California.
  • From its inception, Dyno Therapeutics has been a leader in applying generative AI to advance the frontiers of AAV engineering.
  • The company’s presence at both the ASGCT and SynBioBeta conferences will highlight recent successes from applying machine learning to capsid design, and explore what these applications mean for gene therapy in an era of rapid AI development.
  • At SynBioBeta, Dyno engineers will delve into the reality of ML-driven approaches, highlighting both the promise and challenges that arise when solving real-world problems like in vivo delivery for gene therapies via capsid design.